Skip to main content

Table 1 Clinical and biochemical characteristics of study population according to group of treatment

From: No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

 

25(OH)D group baseline (n = 26)

Placebo group baseline (n = 29)

Age (years)

57.4 ± 10.7

59.8 ± 9.1

Gender (%M)

70 %

60 %

T2D duration (years)

5.9 ± 5.8

6.3 ± 5.4

25(OH)D (nmol/L)

48.15 ± 23.7

40.14 ± 23.9

HFF (%)

7.6 ± 5.7

6.8 ± 5.5

BMI (kg/m2)

29.3 ± 4.4

30.8 ± 4.5

Waist circumference (cm)

100.6 ± 15.2

105.2 ± 12.1

SBP (mmHg)

129.7 ± 16.8

132.2 ± 17.4

DBP (mmHg)

79.2 ± 8.9

82.7 ± 10.7

Total cholesterol (mg/dL)

167.7 ± 37.5

181.6 ± 39.5

HDL-C (mg/dL)

50.3 ± 16.4

49.3 ± 13.2

LDL-C (mg/dL)

93 ± 33.6

105.2 ± 34.5

Triglycerides (mg/dL)

131.5 ± 72.7

133.5 ± 43.8

FBG (mg/dL)

125.3 ± 36.8

135.1 ± 39.9

HbA1c (%/mmol/mol)

6.36 ± 0.9/46 ± 8

6.6 ± 1/48 ± 8

AST (IU/L)

24.12 ± 11.8

23.8 ± 14.6

ALT (IU/L)

31.7 ± 17.1

32.4 ± 26.2

γ-GT (IU/L)

45.3 ± 56.4

35.8 ± 33.3

AST/ALT

0.84 ± 0.3

0.83 ± 0.26

FFAs (μmol/L)

464.6 ± 224.5

519.9 ± 218.4

CK18-M30 (mIU/mL)

212.2 ± 128.2

212.1 ± 155.2

P3NP (pg/mL)

1210.5 ± 1028.6

833.9 ± 955.4

FBI (μU/L)

12 ± 5.1

12.7 ± 5.8

FLI

56.82 ± 26.4

67.7 ± 23.7

HOMA-IR

3.57 ± 1.9

3.87 ± 1.6

HOMA-β%

89.6 ± 63

83.8 ± 63.7

QUICKI

0.33 ± 0.03

0.32 ± 0.02

ADIPO-IR

5.1 ± 3.5

6.3 ± 4.7

CRP (mg/dL)

3.1 ± 3.1

3.6 ± 4.8

Adiponectin (ng/mL)

6.37 ± 3.7

6.4 ± 3.2

VAT area (cm2)

195.9 ± 78.2

191.4 ± 65.9

SAT area (cm2)

229 ± 28.4

258.01 ± 123.9

VAT/SAT ratio

1.07 ± 0.6

1.07 ± 0.62

FMD (%)

5.04 ± 4.5

4.5 ± 3.6

ABI

1.14 ± 0.19

1.1 ± 0.13

IMT (mm)

0.91 ± 0.25

0.87 ± 0.19

  1. Data are presented as mean ± SD, unless indicated otherwise
  2. T2D type 2 diabetes, HFF hepatic fat fraction, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FBG fasting blood glucose, FBI fasting blood insulin, FLI fatty liver index, CRP C reactive protein, VAT visceral adipose tissue, SAT subcutaneous adipose tissue, FMD flow-mediated dilatation, ABI ankle-brachial index, IMT intima-media thickness